Drug Trial Radar · NCT05798923
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Aug 30, 2023
Primary completion
Mar 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- IRulya Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions
PlaceboDrug
Matching placebo administered via dry powder inhalation
LAM-001Drug
LAM-001 administered via dry powder inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the change in PVR at 24 weeksTime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona · Recruiting
Yale New Haven Hospital
New Haven, Connecticut · Active not recruiting
Brigham & Women's Hospital
Boston, Massachusetts · Not yet recruiting
Temple Lung Center, Temple University
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.